Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-10-19
1998-06-02
Peselv, Elli
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 6, 536 61, 536 185, A61K 3170, C07H 1524
Patent
active
057600090
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This invention relates to steroidal glycosides and methods of using the same, particularly as hypocholesterolemic agents and antiatherosclerosis agents, in mammals.
Many known products possessing hypocholesterolemic activity are cross-linked synthetic polymer derivatives, for example of polystyrene. For example, cross-linked, water-insoluble, bile-acid-binding polystyrene-based resins, e.g., Cholestyramine.RTM. agents, have a gritty "mouth-feel", and thus have poor palatability. In addition, these resin beads typically have a low in vivo efficiency. Thus, the effective hypocholesterolemic dose of these materials is excessive, typically 18-24 grams of formulated product per day. Other known polymers having hypocholesterolemic activity include the natural product chitosan and chitosan derivatives as described in European Application pub. no. 0212145. However, the effective hypocholesterolemic dose of these materials is also high.
Other known hypercholesterolemia controlling agents include plant extracts such as "alfalfa saponins". However, these plant extracts are of variable composition and contain significant amounts of nonuseful chemical substances. Due to the variations in composition, it is difficult to set a standard dosage or predict the impurities present. Thus, such extracts are not well suited for use by humans. Further, purification of these extracts would be expensive. As an alternative, certain synthetically produced, pure "sapogenin-derived" compounds, e.g., substances compounded from spirostane, spirostene or sterol-derived compounds, depress cholesterol absorption more effectively than alfalfa extracts on a weight basis and thus can be administered in reasonable sized doses. Because the chemical compositions of these substances are known and because they can be synthesized at a high degree of purity, they are suitable for use by any warm-blooded animal, including humans.
However, unless administered in massive amounts, pure sapogenins do not significantly inhibit cholesterol's absorption. It is only when compounded with another moiety that sapogenins have the desired effect. Examples of such sapogenin compounds are compounds of tigogenin and diosgenin, particularly glycosides thereof. P. K. Kintia, Iu. K. Vasilenko, G. M. Gorianu, V. A. Bobeiko, I. V. Suetina, N. E. Mashchenko, Kim. Pharm. Zh., 1981, 15(9), 55 discloses 3-O-(.beta.-D-galactopyranosyl)hecogenin and its use as a hypocholesterolemic agent. U.S. Pat. Nos. 4,602,003 and 4,602,005 disclose certain steroidal glycosides, in particular 3-O-(.beta.-D-glucopyranosyl)tigogenin and 3-O-(.beta.-D-cellobiosyl)tigogenin and their use for the control of hypercholesterolemia. 3-O-(.beta.-D-cellobiosyl)tigogenin has superior hypocholesterolemic activity when compared to, for example, cholestyramine.
In addition, certain other steroidal glycosides described below have been published, however these publications do not address hypocholesterolemic activity. "Structural Features of the Antioxidant and fungicidal Activity of Steroid Glycosides", Dimoglo, A. S.; Choban I. N.; Bersuker, I. B.; Kintya, P. K.; Balashova, N. N.; Bioorg. Khim, 11(3), 408-413, 1985 discloses rockogenin .beta.-D-galactopyranoside and tigogenin .beta.-D-lactoside. "Preparation and Properties of Some New Steroid .beta.-D-Glucopyranosides, .beta.-D-Glucopyranosiduronic Acids, and Derivatives", Schneider, J. J.; Carb. Research, 17, 199-207, 1971 discloses tigogenin .beta.-D-glucopyranuronoside. "Sterol Glycoside with Activity as Prostaglandin Synthetase Inhibitor", Pegel, K. H. Walker, H.; U.S. Pat. No. 4,260,603, Apr. 7, 1981 discloses hecogenin .beta.-D-glucopyranoside. "Hemolytic Properties of Synthetic Glycosides", Segal, R.; Shud, F.; Milo-Goldzweig, I.; J. Pharm. Sci., 67 (11) 1589-1592, 1978 discloses tigogenin .beta.-D-maltoside, tigogenin .beta.-L-fucopyranoside, smilagenin .beta.-maltoside and tigogenin .alpha.-L-rhamnoside. "Steroid Glycosides from the Roots of Capsicum Annuum II: The Structure of the Capsicosides", Gutsu, E. V.; Kintya, P
REFERENCES:
patent: 4260603 (1981-04-01), Pegel et al.
patent: 4265886 (1981-05-01), Pegel et al.
patent: 4461762 (1984-07-01), Malinow
patent: 4602003 (1986-07-01), Malinow
patent: 4602005 (1986-07-01), Malinow
patent: 5010185 (1991-04-01), Urban
patent: 5502948 (1996-04-01), Matsumurc et al.
patent: 5530107 (1996-06-01), Douglas et al.
patent: 5629295 (1997-05-01), Deninno et al.
"Steroidal Glycosides XX11; Rockogenin Glycosides." Kintya, P.K.; Bobeiko, V.A. Khim, Prir. Soedin, (1) 102-103, 1979.
"Hemolytic Properties of Synthetic Glycosides." Segal, R.; Shud, F.; Milo-Goldzweigh, I.J. Pharm. Sci. 67(11) 1589 1592, 1978.
"Saponins in the Leaves of Agrave Americana." Kintya, P.K.; Bobeiko, V.A.; Krokhmalyuk, V.V.; Chirva, V. Ya. Pharmazie 30(6), 396-7, 1975.
"Steriod Glycosides of the Roots of Capsicum Annuum II: The Structure of the Capsicosides" Gutsu, E.V.; Kintya, P.K.; Lazurevskii, G.V.; Khim. Prir. Soedin. (2), 242-246, 1987.
"Steroidal Saponins from a Cultivated form of Agava Sisalana" Ding, Y.; Chen. Y.Y.; Wang, D.Z.; Yang, C.R. Phytochemistry 28(1), 2787-91, 1989.
"Novel Silver Salts in Glycoside Synthesis" Wulff, G.; Rohlek, G.; Kruger, W. Chem. Ber. 105, 1097-1110, 1972.
The Susceptibility of Cholesterol-Depleted Erythrocytes to Saponin and Sapogenin Hemolysis Segal R.; Milo-Golzweigh, I. Biochem. Biophys. Acta 512, 223-226, 1978.
"Steriod Saponins III: Glycosides A and B from Yucca Filamentosa" Kintya, P.K.; Dragelin, I.P.; Chirva, V. Ya. Khim. Prior. Soedin. (5), 615-16, 1972.
Steroidal Glycosides of Tribulus Terrestirs Linn. Mahato, S.B.; Sahu, N.P.; Ganguly, A.N.; Miyahara, K.; Kawasaki, T.J. Chem. Soc. Perkin Trans. 1 2405-2410, 1981.
"Structural Features of the Antioxidant and Fungicidal Activity of Steriod Glycosides" Dimoglo, A.S.; Choban I.N.; Bersuker, I.B.; Kintya, P.K.; Balashova, N.N. Bioorg. Khim. 11(3), 408-413, 1985.
"Two New Steroidal Glucuronides From Solanum Lyratum; II" Yahara, S.; Morooka, M.; Ikeda, M.; Yamasaki, M.; Nohara, T. Planta Med. (6), 496-8, 1986.
"Preparation and Properties of Some New Steroid Beta-D-Glucopyranosides, Beta-D-Glucopyranosiduronic Acids, and Derivatives" Schneider, J.J. Carb. Research 17, 199-207, 1971.
"Structure Activity Relationships in Steroid Glycosides" Dimolgo, A.S.; Choban, I.N.; Bersuker, I.B.; Kintya, P.K.; Khim. Far., Zh. 19(2), 185-9, 1985.
"Modifiers of Bilayer Lipid Membranes among Steroid Glycosides" Bogatskii, A.V.; Nazarova, N. Yu.; Kintya, P.K.; Bobeiko, V.A. Dokl. Akad. Nauk.
"Steriodal Saponins from Several Species of Liliiflorae Plants" Yang, C.; Li, K.; Ding, Y. Yunnan Ahiwu Yuanjiu Zengkan, Suppl. 3, 13-23, 1990.
"Search for Hypocholesterolemic Agents Among Steriod Glycodies" Kintya, P.K.; Vasilenko, I.K.; Gorianu, G.M.; Bobeiko, V.A.; Suetina, I.V.; Mashchenko, N.E. Kim. Farm. Zh. 15(9), 55-60, 1981.
"Steriod Glycosides from the Leaves of Agave Americana" G.V.; Bobeiko, V.A.; Kintya, P.K. Dokl. Akad. Nauk. SSSR 224(6), 1442-4, 1975.
"Steriod Glycosides form Asparagus Officinalis" Lazurevskii, G.V.; Goryanu, G.M.; Kintya, P.K. Dokl. Akad. Nauk. SSSR 231(6), 1479-81, 1976.
"Steriod Saponins XVII; The structure of Asparagosides D and G." Goryanu, G.M.; Kintya, P.K. Khim. Prir. Soedin, (6), 762-765, 1976.
"The Structure of the Glycosides of Asparagus Officinalis. the Structure of Asparagosides A and B." Goryanu, G.M.; Krokhamlyuk, V.V.; Kintya, P.K. Khim. Prir. Soedin. (3), 400-1, 1976.
"Determination of the Absolute Configuration of a Secondary Hydroxy Group in a Chiral Secondary Alcohol Using Glycosidation Shifts in Carbon-13 NMR Spectroscopy" Seo. S.; Tomita, Y.; Tori, K.; Yoshimura, Y.J. Am. Chem. Soc. 100(11), 3331-3339, 1978.
"Glycosidation Shifts in Carbon-13 NMR Spectroscopy: Carbon-13 Signal from Agylcone and Glucose to Glucoside" Tori, K.; Yoshimura, Y.; Arita, H.; Tomita, Y. Tetrahedr. Lett. (2), 179-182, 1977.
"Chemistry of Ayurvedic Crude Drugs: Part VIII-Shatevari-2: Structure Elucidation of Bioactive Shatavarin-1 and Other Glycosides" Joshi, J.; Dev. S. Ind. J. C
Allen Douglas J. M.
Watson, Jr. Harry A.
Zung Jonathan B.
Benson Gregg C.
Olson A. Dean
Peselv Elli
Pfizer Inc.
Richardson Peter C.
LandOfFree
Spirostanyl glycosidal crystalline monohydrate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spirostanyl glycosidal crystalline monohydrate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spirostanyl glycosidal crystalline monohydrate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1459834